Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $100.57.

Several research analysts have recently weighed in on the stock. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Canaccord Genuity Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research note on Friday, October 30th.

Check Out Our Latest Research Report on KNSA

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $96.33 on Friday. Kiniksa Pharmaceuticals International has a fifty-two week low of $37.02 and a fifty-two week high of $99.31. The business has a 50-day simple moving average of $82.18 and a two-hundred day simple moving average of $62.70. The firm has a market cap of $7.57 billion, a price-to-earnings ratio of 74.10 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. The business had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. As a group, research analysts predict that Kiniksa Pharmaceuticals International will post 1.30 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 77,587 shares of the business’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $93.02, for a total transaction of $7,217,142.74. Following the completion of the sale, the insider directly owned 69,922 shares in the company, valued at $6,504,144.44. The trade was a 52.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 220,170 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $93.27, for a total transaction of $20,535,255.90. Following the sale, the chief executive officer directly owned 780,037 shares of the company’s stock, valued at $72,754,050.99. The trade was a 22.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 842,302 shares of company stock worth $78,587,130. Company insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System bought a new position in Kiniksa Pharmaceuticals International in the third quarter worth approximately $227,000. First Trust Advisors LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 30.7% during the 3rd quarter. First Trust Advisors LP now owns 13,455 shares of the company’s stock worth $1,004,000 after acquiring an additional 3,164 shares during the last quarter. Resona Asset Management Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth $449,000. Focus Advisor Solutions LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $224,000. Finally, Voya Investment Management LLC grew its position in shares of Kiniksa Pharmaceuticals International by 5.5% during the 3rd quarter. Voya Investment Management LLC now owns 8,522 shares of the company’s stock valued at $636,000 after acquiring an additional 445 shares during the period. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

(Get Free Report)

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

Recommended Stories

Analyst Recommendations for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.